Inhibition of MAP4K4 mitigates cardiac insufficiency by promoting S-nitrosylation of Drp1 by inhibiting GPX4 expression, leading to mitochondrial dysfunction and cardiac microvascular disease, thereby exacerbating cardiac insufficiency. Here, DNM1L is linked to heart failure.